|
|

Title: Local delivery of non steroidal anti inflammatory
drugs (NSAIDS) to the colon as a treatment for colonic polyps
United States Patent: 6,231,888
Inventors: Lerner; E. Itzhak (Petah Tikva, IL); Flashner;
Moshe (Petah Tikva, IL); Penhasi; Adel (Bat-Yam, IL)
Assignee: Perio Products Ltd. (Jerusalem, IL)
Appl. No.: 190127
Filed: November 12, 1998
Abstract
A composition and method for the treatment of polyp and colon cancer is
described, such composition and method providing for the colonic delivery
and/or preferential metabolism of a drug or desired agent, especially an
NSAID, in the colon of the patient in need such treatment.
SUMMARY OF THE INVENTION
Recognizing the need for treating colonic polyps in a
manner that results in a minimal number of systemic side effects, and
cognizant of the problem of delivering efficacious levels of drugs to the
colonic environment, the inventors investigated methods by which
therapeutic levels of drugs might be presented to the colonic environment.
These studies cumulated in the discovery of a method of administering
sulindac to a patient in need of same, which method enhances the amount of
sulindac which is converted into the more active metabolite, sulindac
sulfide, in such patient, when compared to the amount that is converted
into sulindac's less active metabolite, sulindac sulfone, in the same
patient, by minimizing the amount of sulindac that is absorbed into the
bloodstream and by maximizing the amount of sulindac that is delivered to
the colon--at which location the sulindac is preferentially metabolized
into sulindac sulfide by the colonic environment and absorbed therefrom.
These studies also cumulated in the discovery of a novel composition or
formulation for the oral administration of a colonic delivery system
(CDS), and method for use of the same, for providing a desired agent to
the colon of human and animal patients in need of the same.
Thus, in a first embodiment, a method is provided for the administration
of sulindac to a patient in need of the same wherein the most if not all
of the dose of sulindac that is administered to such patient is delivered
to the colon of the patient.
In a further embodiment, a composition or formulation designed for oral
administration of a colonic delivery system (CDS) is provided, such
formulation containing the structure of a coated core in which the core
contains a desired agent. The coat of the coated core is based on a
formulation that comprises water insoluble hydrophilic particulate matter
embedded in a water-insoluble carrier; the formulation is such that when
exposed to an aqueous environment, the particulate matter in the coat
absorbs water, thus forming channels that interconnect the inner core with
the outer surface of the coating. These channels allow aqueous solutions
to enter the core and drug to diffuse out.
In a further embodiment, the invention is directed to a method of
administering the compositions as above, wherein the most or all of the
dose of a desired agent is delivered to the colon. In a preferred
embodiment, the colonic contents or cell walls metabolize the drug to a
more desired form, for example, a more active metabolite, such more
desired form thus being synthesized in a preferential manner and locally
higher concentration by such delivery directly to the colon than when the
drug is administered systemically or orally in a conventional manner.
In a further embodiment, the invention is directed to compositions and the
administration of the same as above, wherein the drug is an NSAID.
In a further embodiment, the invention is directed to compositions and the
administration of the same as above, wherein the more active metabolite is
a COX-2 inhibitor.
In a further embodiment, the invention is directed to compositions and
administration of the same as above, wherein the drug and metabolite are
sulindac and sulindac sulfide, respectively.
In a further embodiment, the invention is directed to compositions and
administration of the same as above, especially NSAID and most especially
sulindac, for the treatment and prevention of polyps or cancer, especially
colonic cancer.
Claim 1 of 61 Claims
What is claimed is:
1. A composition or drug delivery device for localized drug release in the
colon, said composition or device comprising one or more drugs in a core,
and a coating surrounding said core, said coating having an outer surface,
wherein said coating comprises water insoluble hydrophilic particulate
matter embedded in a water-insoluble carrier, such that when said
composition or device enters the gastrointestinal tract, said particulate
matter absorbs liquid, thus forming channels that interconnect said core
with said outer surface of said coating, and through which channels, said
one or more drugs are released into the colon, such that at least one of
said drugs is preferentially metabolized to a more active metabolite in
the colon.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|